Morgan Stanley Sticks to Their Hold Rating for Sarepta Therapeutics (SRPT)

In a report released today, Matthew Harrison from Morgan Stanley maintained a Hold rating on Sarepta Therapeutics (SRPTResearch Report), with a price target of $80.00. The company’s shares closed last Friday at $83.59.

According to, Harrison is a 5-star analyst with an average return of 7.4% and a 52.0% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Centessa Pharmaceuticals, BioMarin Pharmaceutical, and Vertex Pharmaceuticals.

Sarepta Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $123.62.

See the top stocks recommended by analysts >>

Sarepta Therapeutics’ market cap is currently $7.2B and has a P/E ratio of -19.12.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Read More on SRPT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More